Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.
Strontium-89 chloride is a radiopharmaceutical that localizes to actively forming new bone, such as metastatic bone lesions from prostate and breast cancer. It provides effective systemic endo-osseous local radiation therapy to these painful lesions. Strontium-89 will soon be available to physicians in the United States for use in the palliative management of metastatic bone pain.
Hansen
D V
DV
Sacred Heart Medical Center, Spokane, Washington.
Holmes
E R
ER
Catton
G
G
Thorne
D A
DA
Chadwick
D H
DH
Schmutz
D A
DA
D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D008297:Male; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000473:pathology*; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
D013326:Strontium Radioisotopes